UNSPSC 85445200: Diagnoses of sedatives, hypnotics and antianxiety drugs

In this classification, this covers the group of activities that yields a diagnosis of sedatives, hypnotics and antianxiety drugs. Sedatives, hypnotics and antianxiety drugs is listed In The World Health Organization's International Statistical Classification of Diseases and Related Health Problems (ICD-10) as a four-character category under code Y47.

ICD-10 also has The following Sedatives, hypnotics and antianxiety drugs children in its four-character category: Y47.0 (Barbiturates, not elsewhere classified); Y47.1 (Benzodiazepines); Y47.2 (Cloral derivatives); Y47.3 (Paraldehyde); Y47.4 (Bromine compounds); Y47.5 (Mixed sedatives and hypnotics, not elsewhere classified); Y47.8 (Other sedatives, hypnotics and antianxiety drugs); Y47.9 (Sedative, hypnotic and antianxiety drug, unspecified)

UNSPSC 85445200 Diagnoses of sedatives, hypnotics and antianxiety drugs is a Class code that shows little relevant recent activity aligned with its nominal scope. The three recent state and local opportunities posted under this code—a diagnostic imaging PACS implementation, special education contracted services across multiple clinical disciplines, and temporary health professional staffing—do not match the code's clinical pharmacology focus. The mismatch suggests either broad miscoding by issuing bodies or that the code is not capturing state and local procurement in its actual therapeutic domain.

The opportunities that do appear under the code span California and Texas public health systems and school districts. San Mateo Medical Center (SMMC) in California posted an RFP for Diagnostic Imaging PACS with proposals due October 21, 2026; Birdville Independent School District in northeast Tarrant County, Texas, solicited special education contracted services (RFP, due October 21, 2026); and Santa Clara County Health System in California established a qualified vendor pool for temporary health professional staffing across ancillary clinical categories (RFQ, due October 7, 2026). None of these opportunities directly concern sedative, hypnotic, or antianxiety pharmaceutical diagnostics or clinical procurement. Until recent solicitations genuinely reflecting the code's therapeutic scope emerge, pursuit under this classification warrants verification that your service offering aligns with what issuing bodies actually intend to buy.